课题基金 / 基金详情

MicroRNA-455-3p and Alzheimer's Disease

MicroRNA-455-3p and Alzheimer's Disease
MicroRNA-455-3p 与阿尔茨海默病
批准号:
10230768
负责人:
P. Hemachandra Reddy
金额:
$58.57万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-15 至 2022-08-31

项目摘要

项目成果

P. Hemachandra Reddy的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 拟议研究的目的是更好地了解microRNA-455-3p(miR-3P)的影响。 455-3p)在阿尔茨海默病(AD)中。AD是一种进行性神经系统疾病,其特征是 在淀粉样蛋白β(Aβ)的产生和Aβ从受AD影响的脑区清除减少,导致突触 损伤,过度磷酸化tau,线粒体结构和功能变化,炎症反应, 放松对microRNAs(MiRNAs)的管制,以及神经元丢失。MicroRNAs在基因组中调节细胞活动 和蛋白质组水平通过调控靶基因。MicroRNAs还参与细胞间和细胞内的相互作用。 细胞内通讯和从脑到细胞外液的运输。在AD状态下, 阿尔茨海默病患者组织内源性miRNAs水平改变,miRNAs释放到外周 系统。非痴呆健康人、受试者血清中全局miRNA分析的初步研究 轻度认知障碍和AD患者发现miR-455-3p随着疾病的增加而上调 进步了。这一上调在其他AD患者的尸检脑中得到证实 脑脊液、AD成纤维细胞和AD B淋巴细胞,以及APP转基因小鼠的大脑中。 随后的初步研究表明,miR-455-3p是APP基因3‘端非编码区的靶点,并且 MiR-455-3p水平的增加增强了线粒体生物发生蛋白和突触蛋白的表达。在 在APP小鼠中,miR-455-3p也被发现通过减少分裂来维持健康的线粒体动力学 蛋白质和通过增加融合蛋白。相反,当内源miR-455-3p的产生 被抑制,突变型APP和Abeta水平升高。然而,目前尚不清楚其分子机制。 当miR-455-3p过表达时细胞的神经保护作用以及当miR-455-3p过表达时细胞内发生了什么机制 455-3P减少。拟议的研究将调查以下3个目标:1)确定 MIR-455-3P在AD衰老和进展过程中的水平,2)确定miR-455-3P的保护作用 抗Aβ和线粒体毒性以及AD进展不同阶段的认知功能障碍,以及3) 确定耗竭miR-455-3p对Aβ和线粒体毒性及认知功能的影响 阿尔茨海默病进展的不同阶段。拟议中的研究将为分子机制提供新的见解。 对miR-455-3P的影响是有益的和有害的。
英文摘要
Project Summary The purpose of the proposed research is to better understand the impact of microRNA-455-3p (miR- 455-3p) in Alzheimer’s disease (AD). AD is a progressive neurological disorder, characterized by an increase in amyloid-β (Aβ) production and reduced clearance of Aβ from AD-affected brain regions, leading to synaptic damage, hyperphosphorylated tau, mitochondrial structural and functional changes, inflammatory responses, deregulation of microRNAs (miRNAs), and neuronal loss. MicroRNAs regulate the cellular events at genomic and proteomic levels through the modulation of targeted genes. MicroRNAs also participate in inter-and- intracellular communication and the transportation from brain to extracellular fluids. In an AD state, endogenous levels of miRNAs change in AD affected tissues, and the miRNAs are released into the peripheral system. A preliminary study analyzing global miRNA in the serum of non-demented healthy persons, subjects with mild cognitive impairment and AD patients found miR-455-3p increasingly upregulated as disease progressed. This upregulation was verified in postmortem brains from additional persons with AD, AD cerebrospinal fluid, AD fibroblasts, and AD B-lymphocytes, and in the brains from APP transgenic mice. Subsequent preliminary studies revealed that miR-455-3p was a target to the 3’UTR of the APP gene and that an increase in miR-455-3p levels enhanced mitochondrial biogenesis proteins and the synaptic proteins. In the APP mice, miR-455-3p also was found to maintain healthy mitochondrial dynamics by decreasing the fission proteins and by increasing the fusion proteins. In contrast, when the production of endogenous miR-455-3p was inhibited, mutant APP and Abeta levels were increased. However, it is unclear, molecular mechanisms of neuroprotection in cells when miR-455-3p is overexpressed and what mechanisms occur in cells when miR- 455-3p is reduced. The proposed research will investigate the following 3 aims: 1) to determine the status of miR-455-3p levels during aging and progression of AD, 2) to determine the protective effects of miR-455-3p against Aβ and mitochondrial toxicities and cognitive dysfunction at different stages of AD progression, and 3) to determine the effects of depleted miR-455-3p on Aβ and mitochondrial toxicities and cognitive function at different stages of AD progression. The proposed studies will provide new insights into molecular mechanisms of miR-455-3p impacts beneficially and deleteriously.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
RLIP, Mitochondrial Dysfunction in Alzheimer’s Disease
MicroRNA Mouse Models and Alzheimer’s Disease
Mitochondrial Molecules in Alzheimer's Disease and Other Tauopathies
Mitochondrial Molecules and Alzheimer's Disease
海外基金